Loading...

MTVA METAVIA INC Expansion Plans 8-K Filing

MTV

MTV

METAVIA INC

(MTVA)

2025 8-K

Clinical Trial Update

Corporate Update

Financial Results Announcement

Clinical Trial Approval

Executive Bonuses Approved

Public Offering Details

Financial Update

Clinical Trial Results

Compliance Regained

Stock Reverse Split

Extension Granted

Positive Trial Results

Corporate Presentation Update

Financial Update

Financial Statements

Market Expansion

Market Expansion

Notification of Non-Compliance

Earnings Releases

Equity Offerings

Product Expansion

Clinical Trial Results

Corporate Update

Clinical Trial Results

Financial Results

Corporate Presentation

Clinical Trial Results

Corporate Presentation

Q3 Financial Results

Clinical Trial Update

Corporate Presentation

Clinical Trial Results

Stockholder Meeting

Q2 2024 Results

Clinical Trial Update

Joint Research Agreement

License Agreement Announcement

Corporate Presentation

Positive Pre-Clinical Data ...

Amendment to Equity Incenti...

Pre-clinical Data Announcement

Earnings Report

Acceptance of Poster Presen...

Clinical Trial Enrollment C...

Financial Results Announcement

Safety Review Committee App...

Appointment of CFO

Clinical Trial Approval

FDA Clearance for Obesity T...

Compliance regained with Na...

Other Special Situation

Reverse Stock Split

Financial Results Announcement

Appointment of Director

Appointment of CFO

Regulation FD Disclosure

Resignation of Director

Lease Agreement and Termina...

Appointment of CEO

Earnings Report

Other Special Situation

Annual Meeting Results and ...

Data Presentation at Scient...

Discontinuation of COVID-19...

Appointment of Director

FDA Clearance for Phase 2a ...

Amendment to Warrants

Other Special Situation

Financial Results Announcement

Regulation FD Disclosure

Resignation and Appointment

External Links:

On August 6, 2025, MetaVia Inc. announced an extension of their Phase 1 clinical trial for DA-1726, increasing the dosing schedule from 4 weeks to 8 weeks, and administering a fifth dose to the first patient. DA-1726 is a treatment aimed at obesity.

AI Assistant

METAVIA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.